Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Categories (click each to see list of all clinical trials associated with that category): Leukemia/MDS/MPD (ONC)
Current Status: Open
Phase: I/II (Cancer Control)
Principal Investigator: Bhatt, Vijaya
Contact Information:
Penny Hardiman, RN
402-559-4135
penny.hardiman@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT03104491?term=NCT03104491&rank=1
Summary
Primary Objective (s) Phase 1: To define a post hematopoietic stem cell transplantation maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) ofinotuzumab ozogamicin in each cohort, respectively.
Phase 2: To assess the efficacy ofinotuzumab ozogamicin as measured by disease-free survival (DFS) at one year in each cohort, respectively.